Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
The new prefilled syringe has the same composition but removes the need for reconstitution, providing a more convenient option for health care providers who administer vaccines. According to the ...
Medpage Today on MSN2d
FDA Adds Guillain-Barre Syndrome Warning to Two RSV VaccinesThe CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
2d
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
4hon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback